
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci Corp demonstrates a promising outlook due to its strong clinical activity signals for ABS-101, which may enhance the probability of success in treating ulcerative colitis (UC) and Crohn's disease (CD) to 15%. The company has produced encouraging preclinical evidence for ABS-201, showcasing its efficacy in promoting hair growth and higher receptor occupancy compared to competing programs, potentially attracting interest from major pharmaceutical companies for partnerships. Furthermore, Absci's commitment to sign at least one deal with a large pharma partner by 2025, along with the expansion of its collaboration with Almirall for additional targets, underlines the company's growth potential in the biologics market.
Bears say
The financial outlook for Absci Corp appears negative primarily due to increased dilution resulting from a recent financing round, which has prompted a reduction in the stock's target price. Furthermore, significant challenges exist in the standard of care for non-hormonal treatment options in the endo market, which may hinder the company's growth potential. This situation is compounded by the high treatment burden on patients, leading to low retention and a preference for more permanent solutions, which could adversely affect Absci's marketable opportunities.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares